Market Closed -
Euronext Paris
11:35:25 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
4.09
EUR
|
-0.73%
|
|
-19.80%
|
-51.02%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
30.42
|
22.84
|
23.75
|
151.6
|
289.9
|
141
|
Enterprise Value (EV)
1 |
34.83
|
26.04
|
31.26
|
130.6
|
193.2
|
105.9
|
P/E ratio
|
96.5
x
|
42.1
x
|
21.3
x
|
5.44
x
|
2.63
x
|
9.08
x
|
Yield
|
-
|
-
|
-
|
1.2%
|
7.6%
|
-
|
Capitalization / Revenue
|
0.99
x
|
0.73
x
|
0.69
x
|
0.99
x
|
0.76
x
|
0.72
x
|
EV / Revenue
|
1.14
x
|
0.83
x
|
0.9
x
|
0.85
x
|
0.5
x
|
0.54
x
|
EV / EBITDA
|
24.8
x
|
31
x
|
17.4
x
|
2.84
x
|
1.36
x
|
2.28
x
|
EV / FCF
|
-
|
-
|
-
|
7,609,916
x
|
2,624,223
x
|
-3,587,726
x
|
FCF Yield
|
-
|
-
|
-
|
0%
|
0%
|
-0%
|
Price to Book
|
1.05
x
|
0.78
x
|
0.78
x
|
2.29
x
|
1.62
x
|
0.87
x
|
Nbr of stocks (in thousands)
|
9,135
|
9,135
|
9,135
|
9,135
|
11,014
|
10,220
|
Reference price
2 |
3.330
|
2.500
|
2.600
|
16.60
|
26.32
|
13.80
|
Announcement Date
|
18-05-23
|
19-05-06
|
20-04-30
|
21-04-21
|
22-04-25
|
23-04-28
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
30.61
|
31.3
|
34.64
|
153.9
|
382.5
|
196.6
|
EBITDA
1 |
1.407
|
0.8389
|
1.797
|
46.02
|
141.8
|
46.49
|
EBIT
1 |
0.9219
|
0.3718
|
1.245
|
45.73
|
140.7
|
38.88
|
Operating Margin
|
3.01%
|
1.19%
|
3.59%
|
29.72%
|
36.77%
|
19.78%
|
Earnings before Tax (EBT)
1 |
0.1
|
0.3714
|
0.8999
|
43.52
|
136.9
|
24.18
|
Net income
1 |
0.3152
|
0.5429
|
1.116
|
31.37
|
104
|
15.66
|
Net margin
|
1.03%
|
1.73%
|
3.22%
|
20.38%
|
27.19%
|
7.96%
|
EPS
2 |
0.0345
|
0.0594
|
0.1221
|
3.050
|
10.01
|
1.520
|
Free Cash Flow
|
-
|
-
|
-
|
17.16
|
73.61
|
-29.53
|
FCF margin
|
-
|
-
|
-
|
11.15%
|
19.24%
|
-15.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
37.28%
|
51.91%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
54.7%
|
70.78%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.2000
|
2.000
|
-
|
Announcement Date
|
18-05-23
|
19-05-06
|
20-04-30
|
21-04-21
|
22-04-25
|
23-04-28
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
4.41
|
3.2
|
7.51
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
21.1
|
96.7
|
35.1
|
Leverage (Debt/EBITDA)
|
3.136
x
|
3.819
x
|
4.179
x
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
17.2
|
73.6
|
-29.5
|
ROE (net income / shareholders' equity)
|
1.18%
|
1.87%
|
3.74%
|
64.8%
|
88.9%
|
9.33%
|
ROA (Net income/ Total Assets)
|
1.44%
|
0.58%
|
1.79%
|
33%
|
44.5%
|
9.18%
|
Assets
1 |
21.89
|
93.44
|
62.23
|
94.97
|
233.7
|
170.5
|
Book Value Per Share
2 |
3.160
|
3.200
|
3.330
|
7.240
|
16.30
|
15.90
|
Cash Flow per Share
2 |
0.2200
|
0.2000
|
0.2000
|
4.020
|
12.80
|
8.500
|
Capex
|
-
|
-
|
-
|
9.12
|
19
|
30.1
|
Capex / Sales
|
-
|
-
|
-
|
5.92%
|
4.97%
|
15.3%
|
Announcement Date
|
18-05-23
|
19-05-06
|
20-04-30
|
21-04-21
|
22-04-25
|
23-04-28
|
|
1st Jan change
|
Capi.
|
---|
| -51.02% | 46.99M | | +0.89% | 12.8B | | -10.29% | 7.61B | | -1.16% | 4.51B | | +5.74% | 4.49B | | -50.70% | 3.3B | | +12.21% | 2.73B | | -16.13% | 2.02B | | -11.50% | 1.73B | | -5.02% | 1.64B |
Diagnostic & Testing Substances
|